The crosstalk between lung cancer and the bone marrow niche fuels emergency myelopoiesis
Modest response rates to immunotherapy observed in advanced lung cancer patients underscore the need to identify reliable biomarkers and targets, enhancing both treatment decision-making and efficacy. Factors such as PD-L1 expression, tumor mutation bu…